SCHEMBL15516640

SCHEMBL15516640

C[Si](C)(C)CCOCOc1ccc(N)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 5/20 0.48
TSHR P16473 2/20 0.48
RAB9A P51151 4/20 0.41
NPC1 O15118 2/20 0.41
MAPT P10636 3/20 0.40
ALDH1A1 P00352 3/20 0.40
KMT2A Q03164 2/20 0.40
APP P05067 4/20 0.39
GAA P10253 2/20 0.39
MAOB P27338 2/20 0.39
MAOA P21397 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MAPK1 P28482 1/20 0.39
CYP3A4 P08684 2/20 0.38
NFE2L2 Q16236 1/20 0.38
ALOX5AP P20292 1/20 0.37
FEN1 P39748 1/20 0.37
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13986929 0.82 KEAP1 (0.49) MAOBNFE2L2
SCHEMBL30279785 0.82 CYP3A4 (0.53) TSHRMAPTALDH1A1APPMAOB
SCHEMBL292142 0.81 TP53 (0.32) CYP3A4ALOX5APFEN1
SCHEMBL2471286 0.81 KDM4E (0.41) TSHRALDH1A1APPMAOBMAPK1
SCHEMBL11889100 0.81 LTA4H (0.46) APP
SCHEMBL8216043 0.81 KCNA3 (0.46) ALDH1A1L3MBTL1
SCHEMBL22198886 0.80 MTNR1A (0.40) RAB9ANPC1MAPTALDH1A1KMT2A
SCHEMBL6041849 0.79 TDP1 (0.33) TDP1TSHRRAB9ANPC1MAPT
SCHEMBL4050696 0.79 TP53 (0.33) KMT2AL3MBTL1MAPK1NFE2L2ALOX5AP
SCHEMBL2133211 0.79 ALDH1A1 (0.45) MAPTALDH1A1MAOBSMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12338247-B2 Modulators of the 5-hydroxytryptamine receptor 7 and their method of use TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2025-06-24 US disclosed
EP-4457223-A1 BCL-2 INHIBITORS Eil Therapeutics, Inc. (US) 2024-11-06 EP disclosed
CN-118451070-A BCL-2 inhibitors 伊尔治疗学股份有限公司 2024-08-06 CN disclosed
WO-2023129553-A1 BCL-2 INHIBITORS Eil Therapeutics, Inc. (US) 2023-07-06 WO disclosed
US-20230112888-A1 NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE PRAEVENTIX, LLC 2023-04-13 US disclosed
EP-2892897-A1 PYRROLONE OR PYRROLIDINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS Bristol-Myers Squibb Company (US) 2015-07-15 EP disclosed
WO-2014039412-A1 PYRROLONE OR PYRROLIDINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230112888-A1 NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE HTR7, HTR5A, HTR6 TDP1 2795/4885TSHR 229/4885RAB9A 2797/4885
US-12338247-B2 Modulators of the 5-hydroxytryptamine receptor 7 and their method of use HTR7, HTR6, HTR5A TDP1 2690/4885TSHR 208/4885RAB9A 3020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.